Want to see TSE:BLAB full AI Analyst Report?
BLAB Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.14
Previous CloseN/A
Volume35.00K
Average Volume (3M)73.07K
Market Cap
C$12.17M
Enterprise ValueC$11.41M
Total Cash (Recent Filing)C$15.89M
Total Debt (Recent Filing)C$248.56K
Price to Earnings (P/E)0.6
Beta-1.28
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)1.93
Price to Sales (P/S)32.95
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low trailing twelve‑month leverage and sizable equity materially reduce refinancing and solvency risk. Over a 2–6 month horizon this resilience gives management flexibility to fund operations, R&D, or strategic deals while cash burn is addressed.
End-to-end Service ModelAn integrated suite across research, formulation, regulatory, testing and analytics creates client stickiness and cross-sell potential. Structurally this supports recurring project pipelines and higher lifetime client value versus single-service providers.
Historical Cash-generation AbilityPast episodes of positive operating and free cash flow indicate the underlying service economics can be profitable. If revenue stabilizes and cost controls are re‑applied, prior cash-positive performance suggests a credible path back to durable cash generation.
Bears Say
Ongoing Cash BurnMaterial negative operating and free cash flow on a TTM basis increases near‑term funding risk and could force dilutive financing or cost cuts. Over several months this constrains investment in capacity, sales, or quality improvements needed to restore growth.
Volatile Revenue And IncomeSignificant swings in revenue and a negative TTM revenue signal undermine predictability and operating leverage. Structural revenue instability complicates contract wins, budgeting, and margin improvement, limiting durable profitability unless stability returns.
Limited Internal ScaleA 28‑person headcount constrains capacity to handle multiple large projects, scale lab operations, and expand sales concurrently. Absent investment to grow the team or outsource, scale limits revenue expansion and margin improvement over the coming months.
Britannia Life Sciences Inc News
BLAB FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
Britannia Life Sciences Inc lowest stock price was C$0.06 and its highest was C$0.14 in the past 12 months.
What is Britannia Life Sciences Inc’s market cap?
Britannia Life Sciences Inc’s market cap is C$12.17M.
When is Britannia Life Sciences Inc’s upcoming earnings report date?
Britannia Life Sciences Inc’s upcoming earnings report date is Aug 04, 2026 which is in 33 days.
How were Britannia Life Sciences Inc’s earnings last quarter?
Britannia Life Sciences Inc released its earnings results on Mar 02, 2026. The company reported C$0.075 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.075.
Is Britannia Life Sciences Inc overvalued?
According to Wall Street analysts Britannia Life Sciences Inc’s price is currently Overvalued.
Does Britannia Life Sciences Inc pay dividends?
Britannia Life Sciences Inc does not currently pay dividends.
What is Britannia Life Sciences Inc’s EPS estimate?
Britannia Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Britannia Life Sciences Inc have?
Britannia Life Sciences Inc has 162,254,330 shares outstanding.
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Britannia Life Sciences Inc reported an EPS of C$0.075 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
Currently, no hedge funds are holding shares in TSE:BLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc., headquartered in Toronto, Canada, offers specialized services in rigorous product evaluation, comprehensive safety analysis, and adherence to regulatory standards. The company supports businesses within the cosmetics, nutraceutical, and consumer packaged goods (CPG) sectors, operating extensively throughout the United Kingdom and various international markets.
Technical Analysis
Options Prices
Currently, No data available
---